EDAP

EDAP TMS SA

EDAP, USA

EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.

https://focalone.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EDAP
stock
EDAP

EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry? simplywall.st

Read more →
EDAP
stock
EDAP

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week marketscreener.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$5.8333

Analyst Picks

Strong Buy

0

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.62

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-21.50 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-30.17 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.64

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 38.96% of the total shares of EDAP TMS SA

1.

Soleus Capital Management, L.P.

(19.5476%)

since

2025/06/30

2.

Morgan Stanley - Brokerage Accounts

(8.9981%)

since

2025/06/30

3.

Rock Springs Capital Management LP

(3.3964%)

since

2025/06/30

4.

Bruce & Co Inc

(1.4807%)

since

2025/06/30

5.

Bruce

(1.4169%)

since

2025/06/30

6.

Apis Capital Advisors, LLC

(0.6052%)

since

2025/06/30

7.

UBS Group AG

(0.4772%)

since

2025/06/30

8.

Schonfeld Strategic Advisors LLC

(0.4604%)

since

2025/06/30

9.

Parkman Healthcare Partners LLC

(0.4141%)

since

2025/06/30

10.

OHE Financial Inc

(0.3609%)

since

2025/06/30

11.

Summit Trail Advisors, LLC

(0.2737%)

since

2025/06/30

12.

Sage Mountain Advisors LLC

(0.2674%)

since

2025/06/30

13.

PSM Growth UI

(0.2139%)

since

2025/06/30

14.

Cetera Investment Advisers

(0.2006%)

since

2025/06/30

15.

Commonwealth Equity Services Inc

(0.185%)

since

2025/06/30

16.

Citadel Advisors Llc

(0.1354%)

since

2025/06/30

17.

Orion Capital Management LLC

(0.1016%)

since

2025/06/30

18.

Simplicity Wealth,LLC

(0.087%)

since

2025/06/30

19.

BNP Paribas Arbitrage, SA

(0.0698%)

since

2025/06/30

20.

INTREPID FAMILY OFFICE LLC

(0.0669%)

since

2025/06/30

21.

Geode Capital Management, LLC

(0.0609%)

since

2025/06/30

22.

Fidelity Nasdaq Composite Index

(0.0609%)

since

2025/07/31

23.

Accredited Investors Inc

(0.0573%)

since

2025/06/30

24.

LUX IM Global Medtech HX

(0.0207%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.